End-stage renal disease following carboplatin chemotherapy for a nasopharyngeal carcinoma

Renal Failure

Volumn 29, Issue 8, 2007, Pages 1049-1051

  Tarrass, Faissal ^a,b   Benmensour, Mostafa ^a   Bayla, Abdelaziz ^a  

^a IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^b NONE   (Morocco)

Author keywords

Carboplatin; Cortical necrosis; End stage renal disease; Hemodialysis

Indexed keywords

CARBOPLATIN;

ADULT; ANAMNESIS; ANURIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CASE REPORT; CLINICAL EXAMINATION; CONTINUOUS INFUSION; DISEASE SEVERITY; ETHMOID SINUS; HEMODIALYSIS; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY CORTEX NECROSIS; KIDNEY FAILURE; KIDNEY TUBULE NECROSIS; MALE; MAXILLA; MULTIPLE CYCLE TREATMENT; NASOPHARYNX; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; SPHENOID SINUS; TREATMENT DURATION; UREMIA;

ADULT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NASOPHARYNGEAL NEOPLASMS;

EID: 36849076826     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701643591     Document Type: Article

References (15)

1. Wolfgang GH, Dominick MA, Walsh KM, Hoeschele JD, Pegg DG. Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Fundam Appl Toxicol. 1994;22:73-79.
2. Martinez F, Deray G, Dubois M, et al. Comparative nephrotoxicity of carboplatin and cisplatin in euvolemic and dehydrated rats. Anticancer Drugs. 1993;4:85-90.
3. Stohr W, Paulides M, Bielack S, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: A report from the late effects surveillance system. Pediatr Blood Cancer. 2007;48:140-147.
4. Agraharkar M, Nerenstone S, Palmisano J, Kaplan AA. Carboplatin-related hematuria and acute renal failure. Am J Kidney Dis. 1998;32:E5.
5. Inbar M, Merimsky O, Chaitchik S. Carboplatin-related idiosyncrasy. Anticancer Drugs. 1995;6:775-776.
6. McDonald BR, Kirmani S, Vasquez M, Mehta RL. Acute renal failure associated with the use of intraperitoneal carboplatin: A report of two cases and review of the literature. Am J Med. 1991;90:386-391.
7. Teo PML, Leung SF, Yu P, Tsao SY, Foo W, Shiu W. A comparison of Ho's, International Union against Cancer, and American Joint Committee Stage Classifications for nasopharyngeal carcinoma. Cancer. 1991;67:434-439.
8. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17:409-422.
9. Frenkel J, Kool G, de Kraker J. Acute renal failure in high dose carboplatin chemotherapy. Med Pediatr Oncol. 1995;25:473-474.
10. Deray G, Ben-Othman T, Brillet G, et al. Carboplatin-induced acute renal failure. Am J Nephrol. 1990;10:431-432.
11. Wright JE, Elias A, Tretyakov O, et al. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol. 1995:36:345-351.
12. Bristol-Myers Squibb. Paraplatin-AQ product monograph. Princeton, NJ; January 2004.
13. Butani L, West DC, Taylor DS. End-stage renal disease after high-dose carboplatinum in preparation of autologous stem cell transplantation. Pediatr Transplant. 2003;7:408-412.
14. Karim M, Vaux E, Davies DR, Mason PD. Renal failure due to scleroderma with thrombotic microangiopathy developing in a woman treated with carboplatin for ovarian cancer. Clin Nephrol. 2002;58:384-388.
15. Thomas H, Boddy AV, English MW, et al. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial. J Clin Oncol. 2000:18:3614-3621.